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ASSESSING THE VALUE OF LASER IN SITU
KERATOMILEUSIS (LASIK) BY PATIENT
REPORTED OUTCOMES
Kang HY1, Cho WH1, Lee JH2, Lee JM2, Park KH2
1Yonsei University, Seoul, South Korea; 2Chungdam
Balgeunsesang Eye Clinic, Seoul, South Korea
OBJECTIVES: To assess the value of laser in situ ker-
atomileusis (LASIK) by patient-reported outcome of
quality of life (QOL). METHODS: This study included
288 consecutive patients receiving LASIK between July
and December 2001 from 2 eye clinics. Myopia-speciﬁc
Quality of Life Questionnaire (MQLQ) was developed,
including 34 questions in 4 domains: visual function and
symptoms, social role function, and psychological well-
being. Baseline QOL for the condition that refractive
error was corrected by glasses or contact lenses before
LASIK were evaluated by self-administered questionnaire.
The evaluation was repeated at 4 days, 1, 3, and 6 months
after LASIK. All question items were rated on a scale
ranging from 1 (maximal dysfunction) to 5 (no dysfunc-
tion). RESULTS: Average score for the global MQLQ
changed from 3.20 preoperatively to 3.75, 4.00, 4.07,
and 4.12 at 4 days, 1, 3, and 6 months after surgery.
Social role function showed the biggest improvement
(score change: 1.48, p = 0.001), followed by psychologi-
cal well-being (0.98, p = 0.001), visual function (0.67, 
p = 0.001) and symptoms (0.49, p = 0.001). Regression
analysis results showed that the degree of uncorrected
visual acuity, astigmatism, and discomfort with vision
preoperatively were signiﬁcant factors affecting the mag-
nitude of changes in QOL after LASIK. CONCLUSIONS:
This study conﬁrms that the value of LASIK is beyond
the clinical achievement of refractive correction and
extended to the improvement of QOL.
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IMPROVEMENT IN VISION TARGETED QUALITY
OF LIFE (QOL) AFTER CATARACT SURGERY
WITH IMPLANTATION OF ACRYSOF® NATURAL
INTRAOCULAR LENS (IOL)
Venkataraman K, Barnes R
ALCON LABS, Fort Worth,TX, USA
OBJECTIVES: Patients suffering from cataracts have
poor visual acuity that impacts their daily functioning and
well-being. Traditional clinical measures such as visual
acuity do not capture patients’ perceptions of visual func-
tioning and health-related quality of life. This paper
focuses on the interim results of a clinical trial examining
the impact of cataract removal surgery and IOL implan-
tation on vision targeted QoL. METHODS: The 39-item
National Eye Institute- Visual Functioning Questionnaire
(NEI-VFQ) consisting of 12 subscales was used to collect
QoL data during a US-Investigational Device Exemption
(US-IDE) trial comparing the Acrysof® Natural single
piece IOL with Acrysof® single piece IOL. QoL data were
collected via trained telephone interviewers once pre-
operatively (baseline) and twice postoperatively after
cataract surgery and IOL implantation (1–2 month, 
and 4–6 month post-operative visits). RESULTS: Interim
analysis results submitted to the US FDA are described
here. On a scale of 0–100, overall vision targeted QoL
measured as an 11 subscale composite (Overall Vision,
Ocular Pain, Near Activities, Distance Activities, Vision
Social, Role Difﬁculties, Mental Health, Dependency,
Driving, Color Vision, and Peripheral Vision), improved
by over 16 percentage points at the 1–2 month post-
operative visit in both treatment groups, and this
improvement was sustained at the 4–6 month post-
operative visit. Additionally, both treatment groups also
showed similar levels of improvements in all the subscale
scores, including the color vision subscale. CONCLU-
SIONS: The study demonstrates that patients receiving
bilateral cataract surgery and implantation of Acrysof®
Natural single piece lens or Acrysof® single piece lens had
measurable improvement in their vision-targeted QoL
and this improvement is sustained.
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OBJECTIVES: Troponin T levels (Tn) are good predic-
tors of outcome in patients with acute coronary sín-
dromes without ST-segment elevation (ACS). Diabetic
patients have demonstrated to carry a worse prognosis
than non-diabetics after having an ACS. METHODS: Tn
were determined in 346 patients (227 men, average age
67.6 years) admitted to hospital after an acute chest pain
episode which was diagnosed as ACS. Plasma sampling
of Tn was made 6 to 24 hours after the clinical episode.
Ninety patients (26%) had diabetes mellitus (D+). Per-
sonal or phone interview of patients or relatives were
obtained three months after the acute episode asking for
endpoints as death, myocardial infarction (MI) or NYHA
III or IV heart failure (HF). RESULTS: Twenty (22.2%)
of all D+ patients had death, MI or HF (RR = 2.7 against
D-; 95% CI = 1.3–5.6; p = 0.008). Tn was equal or higher
than 0.1ng/ml in 133 patients (Tn+ group) and lower
than 0.1ng/ml in the other 213 patients (Tn- group).
Twenty-eight Tn+ patients (21.1%) had death, MI or HF
(RR = 2.8 against T-; 95% CI = 1.6–5.0; p < 0.001).
When age, sex and ST segment changes were also
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included in a logistic regresión, D and Tn remained as the
only independent predictors of outcome. Tn+ lost its pre-
dictive ability in non diabetics (RR = 1.2 against T-; IC
95% = 0.4–3.9; p = 0.77) and increased it in diabetics
(RR = 7.9; IC 95% =1.5–41.0; p = 0.014). In the groups
D-T- and D+T+ the percentage of combinated outcome
were 7.0% and 32.7%, respectively. CONCLUSIONS:
diabetes and Tn are independent predictors of outcome
in the ﬁrst three months after an acute coronary syndrome
without ST segment elevation. Their predictive ability is
additive, so that diabetics with elevated Tn have ﬁve times
the risk of non-diabetics with low Tn. The ability of Tn
to predict major events seems to be lost in non-diabetic
patients.
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NEW TECHNOLOGIES IN THE US MEDICARE:
AN EXAMINATION OF STENT ADOPTION
Linde-Zwirble WT1, Ball D2, Copper LM2
1Health Process Management, Doylestown, PA, USA; 2Eli Lilly
and Co, Indianapolis, IN, USA
OBJECTIVE: The use of cardiac stents is an example of
a technology with both widely discussed cost concerns
and widely adopted use. We examined trends in Medicare
spending overall and for cardiac services from 1995 to
2000 to examine systematic response to the adoption of
this new technology. METHODS: We used all Medicare
hospitalizations from 1995 through 2000. Cases were
identiﬁed for: percutaneous transluminal coronary angio-
plasty (PTCA), stent use, and coronary artery bypass graft
(CABG) surgery. The number of cases, length of stay
(LOS), costs, and total payments were calculated. All
dollar amounts were inﬂated to 2001. RESULTS: Stent
use in PTCA increased from 37% in 1996 to 85% in
2000. The number of PTCAs increased by 91,500 (46%)
from 1995 to 2000 and the number of CABG increased
by 2350 (1.3%). The combined rate for PTCA and CABG
was 12.0 per thousand beneﬁciaries in 2000, an 18.3%
increase since 1995. At $3,000 per case, the cost for stents
was $740 million in 2000. LOS and cost for all PTCAs
decreased from 4.8 days to 3.7 days, and from $14,900
to $13,100. The cost of CABG decreased by $3355 per
case. The cost per beneﬁciary for PTCA and CABG
remained nearly constant and inpatient cardiac care
decreased from $756 per beneﬁciary in 1995 to $698 in
2000. While changes following 1996 cost $1.1 Billion for
stents, other changes in the system saved $6.3 billion.
CONCLUSIONS: While the introduction of stents into
common practice for cardiac care added new costs, com-
pensating changes was induced in the system resulted in
substantial savings. The direct cost of new technologies
is a poor measure of expected system performance. Bal-
anced examination of system costs and clinical perfor-
mance are necessary to avoid irrational fear of short-term
costs at the expense of long-term cost and care 
improvements.
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EFFECTIVENESS OF LIPID-LOWERING THERAPY
IN PRIMARY CARE IN FRANCE
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OBJECTIVE: Cholesterol lowering has been shown 
to reduce cardiovascular morbi-mortality. National and
international (e.g, US NCEP) guidelines have deﬁned
LDL-C treatment initiation levels (TIL) and goals for
patients with different levels of coronary heart disease
(CHD) risk according to the number of CHD risk factors
(CRF) associated to dyslipidemia or to prior CHD. The
objective of this study was to measure the proportions 
of patients above AFSSAPS (French Drug Agency) TIL 
[1CRF > 220mg/dl; 2CRF > 190mg/dl; 3CRFs >
160mg/dl; >3CRFs and prior CHD > 130mg/dl] and
NCEP goal in patients with different CHD risk level and
treated with lipid lowering agents (LLA). METHOD: A
total of 3173 Dyslipidemic patients managed by general
practitioners were randomly selected from a French GPs
computerized database. History of CHD and number of
CRF (age, family history of premature CHD, smoking,
hypertension, HDL-C < 0.9mmol/L, diabetes) were doc-
umented. Percent of patients above AFSSAPS TIL and
NCEP goal was deﬁned for each level of CHD risk.
RESULTS: Twenty-one percent of patients had a history
of CHD. Using AFSSAPS guidelines the distribution of
primary prevention patients according to the number of
CRFs (1, 2, 3, > 3) was 1.6, 25.5, 31.7 and 20.1%, respec-
tively. Almost 40% of CHD patients remained above TIL
and the percentages of primary prevention patients above
TIL varied from 3.9% for patients with 1CRF to 46.5%
for patients with >3CRFs (p < 0.001). Using NCEP guide-
lines, percentage of patients not at goal in the different
CHD risk categories were signiﬁcantly higher and 74.3%
of CHD patients were not at LDL-C treatment goal.
CONCLUSION: Seventy-three percent of patients pre-
scribed LLA were at high CHD risk. Increasing with CHD
risk level, large numbers of patients were above TIL and
LDL-C treatment goal. More effective interventions are
needed in lipid lowering therapy.
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PREVENTION OF DEEP-VEIN THROMBOSIS
AFTER TOTAL KNEE ARTHROPLASTY IN ASIAN
PATIENTS: COMPARISON OF PROPHYLAXIS
WITH LOW MOLECULAR WEIGHT HEPARIN
AND INDOMETHACIN
Wang CJ
Chang Gung Memorial Hospital At Kaosiung,Taiwan
OBJECTIVES: A prospective clinical study was per-
formed to compare the efﬁcacy of low-molecular weight
